ARTICLE | Emerging Company Profile
KalVista: Filling the VEGF void
KalVista developing kallikrein inhibitors for diabetic macular edema
October 17, 2011 7:00 AM UTC
KalVista Pharmaceuticals Ltd. believes its small molecule plasma kallikrein inhibitors will treat diabetic macular edema on par with VEGF inhibitors and will work in more patients. The biotech also hopes to offer injectable and oral delivery options for clinicians.
Diabetic macular edema (DME) is caused by increased permeability of the retinal vasculature, which results in fluid accumulation in the macula and ultimately vision loss...